TELLUS THERAPEUTICS INC

Hillsborough, NC · Founded 2018 · Biotech · Private

Therapeutics for neonatal brain and gut injuries in premature infants

Claim this profile

Follows are private to you and power your alerts

Updated · tellustherapeutics.com

Sector
Biotech
Headquarters
Hillsborough, NC
Founded
2018
Latest Form D
$16M, Feb 2023
Total capital
$19.5M
Federal grants
$1.4M
3 awards · 2020–2021
Rank in peer group#114 of 502
Private capital raised
$18.1M
3 Form D · last Feb 2023
44 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20192020202120222023FEDERAL ↑EQUITY ↓Cumulative $19.5M$313K$697K$384K1st Form D$75K2nd Form D$2M3rd Form D$16M
20192020202120222023FEDERAL ↑EQUITY ↓Cumulative $19.5M$313K$697K$384K1st Form D$75K2nd Form D$2M3rd Form D$16M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$16M
  • Federal grantHealth and Human S · Phase I · Development of a novel therapeutic for treatment of white matter injury in premature infants$384K
  • Private capital raisedForm D · SEC · 2nd filing$2M
  • Federal grantHealth and Human S · Phase I · Development of a novel therapeutic for treatment of white matter injury in premature infants$697K
  • Federal grantHealth and Human S · Phase I · Development of a novel therapeutic for treatment of white matter injury in premature infants$313K
  • Private capital raisedForm D · SEC · 1st filing$75K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grants#114 · top 23%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Jason E. KralicResearcherExecutive Officer, DirectorLinked by $1.4M in grants as PI
  • Alex M. RuckdaeschelDirectorNamed in SEC Form D filings
  • Chris J. GarabedianDirectorNamed in SEC Form D filings
  • Eric J. BennerExecutive Officer, DirectorNamed in SEC Form D filings
  • Fred J. CalloriDirectorNamed in SEC Form D filings
  • Jason E. KarlicExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Hemostemix Inc.Similar federal contract value in Biotech · null in contracts
  • ONCOSYNERGY, INC.Similar federal contract value in Biotech · null in contracts
  • DATIRIUM LLCSimilar federal contract value in Biotech · null in contracts
  • IBEX BIOSCIENCES, LLCSimilar federal contract value in Biotech · null in contracts
  • RESONANT THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
  • VALITOR, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .